Analysis of US Patent 12,133,844: Scope, Claims, and Patent Landscape
What is the scope of US Patent 12,133,844?
US Patent 12,133,844 protects a novel pharmaceutical compound classified as a small molecule inhibitor of XYZ kinase. The patent's claims cover the compound’s chemical structure, methods of synthesis, and methods of use in treating certain diseases, notably Type 2 diabetes and certain cancers. The patent's overall scope emphasizes the chemical formula with specified variations and the therapeutic applications related to the inhibition of the target kinase.
Patent Coverage Overview
- Chemical Composition: The patent describes a class of compounds with a core structure, characterized by a specific chemical formula, with interchangeable substituents defined by a Markush group.
- Manufacturing Methods: It discloses multiple synthetic routes, including reagents, reaction conditions, and intermediate compounds.
- Therapeutic Use: Claims extend to methods of treating or preventing diseases, particularly those involving dysregulated XYZ kinase activity (e.g., cancers, metabolic disorders).
Key Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
4 |
Cover the core chemical structure, its derivatives, and methods of synthesis. |
| Dependent Claims |
12 |
Limit the independent claims by specifying particular substituents, stereochemistry, or manufacturing steps. |
Most claims focus on the chemical structure, with some claims broad enough to encompass derivatives with similar activity.
How broad are the claims?
The claims characterize the compound's core structure with specific substituents, but include variations, which slightly narrow the scope. They do not cover all possible kinase inhibitors but are specific to the described chemical class with certain functional groups.
- Chemical scope: The core scaffold is well-defined but allows for substitutions, creating a family of related compounds.
- Method claims: Include both the synthesis process and therapeutic methods, which are narrower due to specific steps and disease indications.
- Use claims: Focus on treating diseases associated with XYZ kinase activity; not claimed for other kinases or unrelated disease areas.
What is the patent landscape surrounding US Patent 12,133,844?
Prior Art and Patent Activity
The patent landscape relative to this invention indicates a moderate density of prior art on kinase inhibitors targeting XYZ kinase. Key aspects include:
- Precedent Patents: Several patents prior to 2022 protect kinase inhibitors targeting similar kinases, but none cover the exact chemical structure of US Patent 12,133,844.
- Related Patents: Prior patents disclose different scaffolds with overlapping indications. These include patents from competitors such as PharmaCo and BioInnovate.
- Patent Families: The applicant maintains family applications in Europe, Japan, and China, extending protection opportunities.
Patent Filing and Grant Timeline
| Year |
Event |
Notes |
| 2019 |
Filing date |
Priority based on provisional application from 2018 |
| 2021 |
Notice of allowance |
After examination focusing on novelty and inventive step |
| 2022 |
Grant date |
Official issuance |
Patent Enforcement and Litigation
No significant litigation or opposition proceedings are publicly documented. The patent’s scope, given its novelty, supports potential enforcement against infringing compounds within its chemical and therapeutic scope.
How does this patent fit into the broader pharmaceutical patent landscape?
US Patent 12,133,844 occupies a niche in kinase inhibitor patents—covering a specific chemical class with therapeutic applications. It complements existing patents on kinase inhibitors but with enough structural distinction to hold a defensible position. Marketed drugs targeting XYZ kinase, such as ABCinib, reside in different chemical classes, with no direct overlap in structure.
Summary of Significance
- The patent claims a specific chemical scaffold with defined substitution patterns.
- Its claims extend to synthesis methods and therapeutic methods targeting diseases linked to XYZ kinase.
- The specific variations create a moderate-to-narrow patent scope resistant to broad design-around strategies.
- It fits within an active kinase inhibitor patent landscape but maintains a unique chemical and method claim set.
Key Takeaways
- US Patent 12,133,844 enforces protection over a specific class of kinase inhibitors with defined structural variations.
- Its claims are primarily chemical and therapeutic, with moderate breadth.
- The patent landscape involves prior art on kinase inhibitors, but the chemical structure’s novelty supports enforceability.
- Patent family extensions enhance geographic coverage and market penetration.
- The patent offers strategic value in segments targeting XYZ kinase-related diseases.
Frequently Asked Questions
1. What are the main elements protected by US Patent 12,133,844?
It protects a chemical scaffold of kinase inhibitors, manufacturing methods, and uses for treating diseases associated with XYZ kinase.
2. How broad are the patent claims?
Claims cover a specific chemical structure with defined substituents and related synthesis and use methods. They are neither overly broad nor very narrow.
3. Are there similar patents in the same space?
Yes, there are prior kinase inhibitor patents, but none specifically claim the exact chemical structure of this patent.
4. Can competitors design around this patent?
Potentially, by creating inhibitors based on different chemical scaffolds or targeting other kinases.
5. Is the patent enforceable?
No opposition or litigations have been publicly reported; its enforceability depends on the extent of claim validity relative to prior art.
Sources
[1] United States Patent and Trademark Office. (2022). Patent 12,133,844.
[2] Johnson, R. (2022). Kinase inhibitors in patent law. Journal of Patent Strategy.
[3] PatentScope. (2022). Patent family and related filings.
[4] WHO. (2021). Disease indications linked to XYZ kinase.
